文献速递肿瘤 PET/CT核素与放射性配体治疗

神经母细胞瘤患者接受177Lu-DOTATATE治疗后123I-MIBG SPECT/CT假阴性而68Ga-DOTATATE PET/CT真阳性一例

A False-Negative 123 I-MIBG SPECT/CT With True-Positive 68 Ga-DOTATATE PET/CT in a Patient With Neuroblastoma Following 177 Lu-DOTATATE Therapy.
PubMed 文献 · Clin Nucl Med · 2024-08-02

一名10岁高危神经母细胞瘤女孩,123I-MIBG SPECT/CT与68Ga-DOTATATE PET/CT均显示多发骨转移;接受177Lu-DOTATATE治疗后,仅68Ga-DOTATATE PET/CT发现残留病灶,而123I-MIBG SPECT/CT结果为阴性。该病例强调177Lu-DOTATATE治疗后68Ga-DOTATATE PET/CT与123I-MIBG SPECT/CT的互补作用。

要点

  • 10岁高危神经母细胞瘤女孩,治疗前两种影像均显示多发骨转移。
  • 177Lu-DOTATATE治疗后,68Ga-DOTATATE PET/CT检出残留病灶,123I-MIBG SPECT/CT为阴性。
  • 病例强调177Lu-DOTATATE治疗后68Ga-DOTATATE PET/CT与123I-MIBG SPECT/CT的互补作用。

核心结论

  • 病例强调177Lu-DOTATATE治疗后68Ga-DOTATATE PET/CT与123I-MIBG SPECT/CT的互补作用。

研究设计与样本

  • 一例10岁高危神经母细胞瘤女孩的病例报告,先后行123I-MIBG SPECT/CT与68Ga-DOTATATE PET/CT,并在177Lu-DOTATATE治疗后复查。

主要发现

  • 治疗前123I-MIBG SPECT/CT与68Ga-DOTATATE PET/CT均显示多发骨转移。
  • 177Lu-DOTATATE治疗后,仅68Ga-DOTATATE PET/CT识别残留病灶,123I-MIBG SPECT/CT结果为阴性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 10-year-old girl with high-risk neuroblastoma underwent 123 I-MIBG SPECT/CT and 68 Ga-DOTATE PET/CT, which both showed multiple bone metastases. However, following 177 Lu-DOTATATE therapy, only 68 Ga-DOTATATE PET/CT identified residual lesions with negative 123 I-MIBG SPECT/CT results. The case emphasized the complementary role of 68 Ga-DOTATATE PET/CT and 123 I-MIBG SPECT/CT after 177 Lu-DOTATATE therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Li S, Xu Y, Lu X, et al. A False-Negative 123 I-MIBG SPECT/CT With True-Positive 68 Ga-DOTATATE PET/CT in a Patient With Neuroblastoma Following 177 Lu-DOTATATE Therapy. Clin Nucl Med. 2024. PMID: 39093037. doi:10.1097/RLU.0000000000005397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。